Drug-drug interaction between ensitrelvir and tacrolimus in a patient undergoing treatment for COVID-19: a case report

Abstract Background Ensitrelvir is a novel SARS-CoV-2 3-chymotrypsin-like protease inhibitor, similar to nirmatrelvir/ritonavir. Several case reports have demonstrated the efficacy of 3-chymotrypsin-like protease inhibitors in treating prolonged coronavirus disease 2019 (COVID-19) in immunocompromis...

Full description

Bibliographic Details
Published in:Journal of Pharmaceutical Health Care and Sciences
Main Authors: Yuki Miyata, Ryo Yamaguchi, Takehito Yamamoto, Toshiyuki Kishida, Kazuhiko Ikeuchi, Hiroaki Harada, Takeya Tsutsumi, Keishi Fujio, Tappei Takada
Format: Article
Language:English
Published: BMC 2025-01-01
Subjects:
Ensitrelvir
Tacrolimus
COVID-19
Drug-drug interaction
Cytochrome P450 3A
P-glycoprotein
Online Access:https://doi.org/10.1186/s40780-025-00411-y

Internet

https://doi.org/10.1186/s40780-025-00411-y

Similar Items